Premium
Cephaloridine (Loridine)
Publication year - 1968
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196896819
Subject(s) - cephaloridine , azotemia , nephrotoxicity , medicine , renal function , impaired renal function , urology , intensive care medicine , kidney , chemistry , cephalosporin , antibiotics , biochemistry
Because of nephrotoxicity (e.g., tubular necrosis) of cephaloridine at closes above 4 Gm. daily (see Warnings and Adverse Reaction), recommended doses should not be exceeded. Patients with known or suspected impairment of renal function should be under close clinical observation for changes in renal function, or be hospitalized. If impaired renal function develops during therapy, cephaloridine should be discontinued. Cephaloridine should not be used in patients with azotemia.